Reducing inflammation helps create a regenerative environment in the Central Nervous SystemTORONTO and HAIFA, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced new laboratory data demonstrating that its proprietary exosomes can significantly reduce inflammatory activity compared to untreated cells and cells treated with a commercially available exosome product. “Inflammation and regeneration are conflicting bi ...

As Nike, Inc. ( NKE ) fell more than 10% during after-hours and the day following its Fiscal Q2 report , wiping out $10 billion in market value, I could not help butExcellent academic Finance background and Finance professional with over five years of cumulative experience in Consulting & Audit Firms including a professional Valuation position, FP&A and Controlling positions, and Financial writing.My approach is mostly value-oriented. However, valuation is rarely an appropriate short- to mid-term timing ind ...

Fort Lauderdale, Florida, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Vine Hill Capital Investment Corp. II (the “Company”), a special purpose acquisition company, today announced the closing of its upsized initial public offering of 23,000,000 units at a price of $10.00 per unit, including 3,000,000 units issued pursuant to the exercise of the underwriters’ over-allotment option in full. The units began trading on the Nasdaq Global Market (“Nasdaq”) under the ticker symbol “VHCPU” on December 18, 2025. Each unit con ...

Core Insights - The U.S. Food and Drug Administration (FDA) has granted national priority vouchers to Merck's cholesterol pill and cancer therapy, marking them as the latest additions to the fast-track program [1] Group 1: Company Developments - Merck's cholesterol pill and cancer therapy have received national priority vouchers from the FDA, which may expedite their development and approval process [1] Group 2: Industry Implications - The granting of national priority vouchers indicates a supportive regulatory environment for innovative therapies in the pharmaceutical industry, potentially leading to faster market access for new treatments [1]

Skyworks Solutions (NASDAQ:SWKS) snapped six straight sessions of losses, as the company’s shares closed 0.31% higher at $64.69 on Friday. In the preceding six sessions, the company lost over 6.28%, compared to a 1.63% drop in the S&P 500 Index. Similarly, shares of the company ...

Core Insights - The global luxury goods sector is experiencing a prolonged slowdown in 2025, with personal luxury goods spending expected to remain flat at approximately €1.44 trillion ($1.56 trillion) after a contraction in 2024, marking one of the weakest cycles since the Great Recession [1][4] - Despite the current challenges, forecasts indicate a potential rebound in 2026, driven by renewed demand in emerging markets and early signs of recovery in Chinese consumption patterns [2][4] Industry Overview - The luxury sector is anticipated to grow between 3% and 5% in 2026, a significant improvement from the flat performance in 2025, with emerging markets, particularly Asia Pacific, playing a crucial role [4][6] - Leading brands are adjusting strategies by easing aggressive price hikes and refreshing product assortments to re-engage consumers [5][10] - The U.S.-China trade dynamics are expected to stabilize, reducing cost uncertainties for luxury goods companies and creating a more favorable environment for global luxury demand [7][10] China Market Dynamics - China's luxury goods market, valued at hundreds of billions of U.S. dollars, is positioned for mid- to long-term growth, supported by an expanding middle class and increased digital retail penetration [8][10] - Domestic luxury spending in China stabilized in the latter half of 2025, indicating potential for renewed growth in 2026 [9][10] Company-Specific Insights - **Kering**: Expected to benefit from a rebound in 2026, particularly through its Gucci brand, with projected earnings growth of 35.2% on revenue growth of 1.4% [11][12] - **Richemont**: The company's jewelry division remains resilient, and easing tariff uncertainties may alleviate previous pressures on its share price, with expected earnings growth of 10.3% on revenue growth of 6.8% in fiscal 2027 [13][14] - **Burberry**: Undergoing a brand repositioning, Burberry could see a significant tailwind from stabilization in China and emerging markets, with projected earnings growth of 67.9% on revenue growth of 3.9% in fiscal 2027 [15][16]

Key Takeaways Micron Technology posted 56.8% revenue growth as AI-driven HBM demand lifted cloud memory sales and results.Palantir Technologies saw 63% revenue growth on strong U.S. commercial adoption and expanding government work.MU forecasts higher Q2 2026 revenue and EPS, supported by record free cash flow for future growth plans. The artificial intelligence (AI) boom has significantly boosted Micron Technology, Inc. (MU) and Palantir Technologies Inc. (PLTR) , with their shares soaring 195.3% and 145.5 ...

MILWAUKEE--(BUSINESS WIRE)--The Manitowoc Company, Inc. (NYSE: MTW) announced today that the European Commission launched an anti-dumping investigation into imports of mobile cranes from China following a complaint filed by leading European mobile crane manufacturers, represented by the VDMA Materials Handling and Intralogistics Association. VDMA's press release can be accessed here. The current trade complaint focuses on mobile cranes designed for the lifting and moving of materials on land, w. ...

WAYNE, Pa., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading today, December 19, 2025. The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® that are classified as either biotechnology or pharma ...

SAN FRANCISCO--(BUSINESS WIRE)--Okta, Inc. (Nasdaq: OKTA), the leading independent identity partner, today announced the appointment of Rob Bernshteyn and Paul Sagan to the Company's board of directors, effective December 19, 2025. "Rob and Paul bring a wealth of operational experience across SaaS, cybersecurity, and AI that will help drive Okta's next phase of growth,†said Todd McKinnon, Okta CEO and Co-Founder. "Their expertise comes at a pivotal moment, as identity becomes the foundation for secure AI. W ...